<DOC>
	<DOCNO>NCT02490839</DOCNO>
	<brief_summary>Up , randomize , large scale study prospectively simultaneously compare efficacy , adverse effect patient adherence high-dose dual therapy ( HDDT ) bismuth-containing quadruple therapy ( BQT ) rescue regimen H. pylorus eradication . The aim study : 1. compare efficacy HDDT , BQT rescue regimen H. pylori eradication ; 2. compare patient adherence adverse effect treatment regimens ; 3. investigate factor may influence H. pylorus eradication treatment regimen .</brief_summary>
	<brief_title>Efficacy High-dose Dual Therapy v Bismuth-containing Quadruple Therapy Rescue Treatment Hp Infection</brief_title>
	<detailed_description>Participants , age â‰¥ 20 , H. pylori-positive chronic gastritis with/without peptic ulcer ( duodenal gastric ulcer ) recruit . All undergo endoscopy biopsy rapid urease teat , histology , bacterial culture treatment . Four eight week termination treatment , H. pylori infection status examine 13C-urea breath test . The CYP2C19 genotype participant analyze polymerase chain reaction-based restriction fragment length polymerase ( PCR-RFLP ) method . A compute generated random number sequence block two subgroup , say A , B . If patient fail anti-H. pylori therapy previously , invite enter study evaluate efficacy rescue regimen . Participant meet inclusion criterion one exclusion criterion randomize receive one follow regimen : group A- HDDT ( rabeprazole 20 mg qid + amoxicillin 750 mg qid 14 day ) ; group B- BQT ( rabeprazole 20 mg qid + tripotassium dicitrate bismuthate 300 mg qid + metronidazole 250 mg qid + tetracycline 500 mg qid 10 day ) ; All participant ask complete questionnaire record symptoms drug consumption daily treatment period . Post-treatment , participant follow Outpatients Clinic investigate patient adherence adverse effect treatment .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Helicobacter Infections</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Tetracycline</mesh_term>
	<mesh_term>Amoxicillin</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<mesh_term>Bismuth</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>Inclusion criterion : 1 . Participants H. pylorus relate chronic gastritis with/without peptic ulcer age great 20 year old willing receive eradication therapy . Exclusion criterion : 1. pregnant nursing woman 2. serious concomitant illness malignant tumor kind 3. history hypersensitivity test drug 4. serious bleed course ulcer 5. previous gastric surgery 6. receive bismuth salt , PPIs , antibiotics previous month .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Helicobacter pylorus</keyword>
	<keyword>high dose dual therapy</keyword>
	<keyword>bismuth-containing quadruple therapy</keyword>
	<keyword>antibiotic resistance</keyword>
</DOC>